DRL posts strong 77% profit growth to Rs 1,247 cr riding on US, Russia

Firm says sustained focus on improving productivity has also helped boost profits; DRL is now bullish on its biosimilars and hopes to start filing for them in US in the coming quarters

Hyderabad based Dr Reddy’s Laboratories posted a strong net profit growth of 77 per cent year on year to Rs 1,247 crore riding on the back of a 27 per cent rise in revenues largely driven by the North American and Russian markets. The company said its continued focus on improving productivity has also helped boost the profits.

DRL is now bullish on its biosimilars business and hopes to start filing for these products in the US in the coming quarters, and has also finished the phase one clinical trials of tocilizumab, a monoclonal antibody used for the treatment of